At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 441 enrolled
Drug / intervention
solifenacin succinatedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label Multicenter Study to Assess the Efficacy and Safety of Daily Oral Administration of 5 and 10mg VESIcare® (Solifenacin Succinate) in Patients Who Wish to Switch From Detrol LA® (Tolterodine Tartrate Extended Release) for the Treatment of Overactive Bladder Symptoms Versus: VESIcare® Efficacy and Research Study US
In Brief
A Phase 3 clinical trial evaluating solifenacin succinate for Urinary Bladder, Overactive. Completed, enrolled 441 participants across 104 sites.
Detailed Summary
To evaluate the efficacy of 5 and10mg solifenacin succinate in patients with urgency who have OAB syndrome (urgency, with or without urge incontinence, usually with frequency and nocturia) and wish to switch from tolterodine tartrate extended release to solifenacin succinate due to lack of sufficient improvement in urgency episodes
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsUrinary Bladder, Overactive
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJun 2004
Primary CompletionAug 2005
First PostedApr 2007
TodayJul 2026
First PostedApr 2, 2007
Enrollment StartJun 1, 2004
Primary CompletionAug 1, 2005
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 19.3 years ago
Interventions
solifenacin succinatedrug
Oral